# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2023 Earnings Results

**Report date:** 2023-05-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2023

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.14%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $10.09 | N/A | +30.87% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product pipeline. However, they acknowledged market challenges that could impact future performance.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in R&D to drive future growth.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported a strong earnings per share, exceeding expectations significantly. However, the stock fell by over 6% in reaction, likely due to the absence of revenue details and guidance. Investors may be cautious as the company navigates market challenges despite the positive EPS surprise.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2023_